New shot aims to calm immune attack on kidneys
NCT ID NCT05668403
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called B007, given as a shot under the skin, for people with primary membranous nephropathy — a kidney disease where the immune system attacks the kidneys. The study will include 52 adults and will focus on safety, how the drug moves through the body, and whether it shows any early signs of helping. Because it is a Phase 1 trial, the main goal is to find a safe dose, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
B007 (a lab-made antibody that targets CD20 on immune cells)
What this could lead to
If it works, this could point toward a new treatment option for primary membranous nephropathy that is easier to take (as a shot under the skin).
What could go wrong
This is a very early Phase 1 trial with only 52 people, focused on safety and dosing. It is too soon to know if the drug will actually help the disease, and there may be side effects from targeting immune cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hebei General Hospital
RECRUITINGShijiazhuang, Hebei, 050057, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Longhua Hospital Shanghai University of Traditional Chinese Medicine
RECRUITINGShanghai, 200032, China
-
Longhua Hospital Shanghai University of Traditional Chinese Medicine
RECRUITINGShanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking university first hospital
RECRUITINGBeijing, 100010, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, He'nan, 410100, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital,College of Medicine,Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••